Boston Scientific (BSX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Boston Scientific

NYSE•Healthcare•Medical Devices

$43.55-0.36(-0.01%)After hours

Market Cap

$64.03B

P/E

17.5x

P/S

3.0x

P/B

2.6x

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

How this company scores

ExcellentMetricSide Score: 89/100

Strongest: Profitability (23/25); weakest: Cash & Earnings Quality (21/25).

Profitability23/25

Growth23/25

Balance Sheet & Red Flags22/25

Cash & Earnings Quality21/25

Strengths

Strong marginsRising earningsLow leverageInterest easily covered

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 17.5x5y range 17.5x – 95.0x

Currently below its 20-quarter median.

P/S · 3.0x5y range 3.0x – 8.6x

Currently below its 20-quarter median.

P/B · 2.6x5y range 2.6x – 7.2x

Price & Volume

Market Cap $64.03B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $21.00B
Q. Revenue: $5.44B
TTM EBITDA: $5.57B
TTM Op. Income: $4.15B
Q. Op. Income: $1.18B
TTM Net Income: $3.67B
Q. Net Income: $905.00M
EPS: $0.62
Shares Out.: $1.47B

$21.00B in TTM revenue grew 13.5% YoY, reaching $5.44B last quarter. TTM EBITDA of $5.57B and TTM operating income of $4.15B show growth is flowing through to the bottom line. TTM net income of $3.67B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 70.7%
EBITDA Margin: 28.2%
Op. Margin: 21.6%
Net Margin: 16.6%

Op. margin of 21.6% is up 5.5% YoY — cost efficiency is improving. Net margin at 16.6% and gross margin of 70.7% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 17.5x
P/S Ratio: 3.0x
P/B Ratio: 2.6x

At 17.5x P/E, the stock trades within typical market levels. P/S of 3.0x and P/B of 2.6x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 5 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $45.22B
Cash: $539.00M
Long-Term Debt: $10.91B
Book Value: $24.69B
D/E Ratio: 0.4
Debt/EBITDA: 7.1

With $45.22B in assets and $10.91B in long-term debt, D/E is 0.4and book value is $24.69B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 12% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.47B
TTM Free Cash Flow: $3.63B
FCF Margin: 17.3%
FCF / Net Income: 1.0

TTM FCF of $3.63B on $1.47B in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 4% — an improving trend.